Role of the mucins in pathogenesis of COPD: implications for therapy
File(s)
Author(s)
Type
Journal Article
Abstract
Introduction: Evidence accumulated in the last decade has started to reveal the enormous complexity in the expression, interactions and functions of the large number of different mucins present in the different compartments of the human lower airways. This occurs both in normal subjects and in COPD patients in different clinical phases and stages of severity.
Areas covered: We review the known physiological mechanisms that regulate mucin production in human lower airways of normal subjects, the changes in mucin synthesis/secretion in COPD patients and the clinical efficacy of drugs that modulate mucin synthesis/secretion.
Expert opinion: It is evident that the old simplistic concept that mucus hypersecretion in COPD patients is associated with negative clinical outcomes is not valid and that the therapeutic potential of ‘mucolytic drugs’ is under-appreciated due to the complexity of the associated molecular network(s). Likewise, our current knowledge of the effects of the drugs already available on the market that target mucin synthesis/secretion/structure in the lower airways is extremely limited and often indirect and more well-controlled clinical trials are needed in this area.
Areas covered: We review the known physiological mechanisms that regulate mucin production in human lower airways of normal subjects, the changes in mucin synthesis/secretion in COPD patients and the clinical efficacy of drugs that modulate mucin synthesis/secretion.
Expert opinion: It is evident that the old simplistic concept that mucus hypersecretion in COPD patients is associated with negative clinical outcomes is not valid and that the therapeutic potential of ‘mucolytic drugs’ is under-appreciated due to the complexity of the associated molecular network(s). Likewise, our current knowledge of the effects of the drugs already available on the market that target mucin synthesis/secretion/structure in the lower airways is extremely limited and often indirect and more well-controlled clinical trials are needed in this area.
Date Issued
2020-05-03
Date Acceptance
2020-03-05
Citation
Expert Review of Respiratory Medicine, 2020, 14 (5), pp.465-483
ISSN
1747-6348
Publisher
Taylor and Francis
Start Page
465
End Page
483
Journal / Book Title
Expert Review of Respiratory Medicine
Volume
14
Issue
5
Copyright Statement
© 2020 Informa UK Limited, trading as Taylor & Francis Group. This is an Accepted Manuscript of an article published by Taylor & Francis in
Expert Review of Respiratory Medicine on 19 March 2020, available online: https://doi.org/10.1080/17476348.2020.1739525
Expert Review of Respiratory Medicine on 19 March 2020, available online: https://doi.org/10.1080/17476348.2020.1739525
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000527126000004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Respiratory System
MUC5AC
MUC5B
mucoactive drugs
OBSTRUCTIVE PULMONARY-DISEASE
NONTYPABLE HAEMOPHILUS-INFLUENZAE
RESPIRATORY SYNCYTIAL VIRUS
MUC5B PROMOTER POLYMORPHISM
GOBLET CELL-DIFFERENTIATION
MUCUS SECRETION
CIGARETTE-SMOKE
N-ACETYLCYSTEINE
AIRWAY INFLAMMATION
GROWTH-FACTOR
Publication Status
Published
Date Publish Online
2020-03-19